



CIN : L99999MH1951PLC008485

Regd. Office : A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India

Tel : +91-22-67980888 , ● Fax : +91-22-67980899 , ● Email : contact@dil.net , ● Website: www.dil.net

Ref: DIL:DIL/BSE/2018-19/F.No.:49

February 12, 2019

**Corporate Relations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001**

Dear Sir,

Sub.: Intimation of Earnings Release dated February 12, 2019

Ref: Scrip Code: 506414

Further to our intimation dated February 12, 2019 regarding approval of Unaudited Financial Results (Standalone and Consolidated) by the Board of Directors for the quarter and nine months ended December 31, 2018, we hereby enclose a copy of Earnings Release of the Company for the quarter ended December 31, 2018.

The said Earnings Release is also available on Company's website www.dil.net

Kindly take the same on records.

Thanking you,

Yours faithfully,
for **DIL LIMITED**

Srikant N Sharma
Company Secretary
CS Membership No: F3617
A-1601, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610


Encl: As above

DIL Limited

Strong Momentum Continues in 9M FY19

Consolidated Financial Performance

- Total Revenue (including other income) up by 54 % YoY to Rs. 324 Cr
- EBITDA (including other income) grew by 116 % YoY to Rs. 129 Cr, margin is at 40%
- PAT grew by 173 % YoY to Rs. 79 Cr




*Includes other income

9M FY19 Revenues and Profitability have surpassed FY18

Earnings Release

Mumbai – 12th February 2019 – Results of Fermenta Biotech Limited, 91.2% Subsidiary of DIL Limited

Fermenta Biotech Limited (FBL) manufactures Vitamin D3 (Cholecalciferol), the only manufacturer and supplier in India and amongst the top few manufacturers in the world. Apart from Vitamin D3, it also manufactures niche APIs, and is a major supplier of Penicillin G Amidase, Polymer supports and Enzyme technologies for beta lactams and Bio-Enzymes for environmental solutions.



*Includes other income

Fermenta Biotech Limited							
Particulars (Rs. Crs)	Q3 FY19	Q3 FY18	YoY%	9M FY19	9M FY18	YoY%	FY18
Revenue*	106.3	96.4	10%	312.6	204	53%	300.48
EBITDA*	44.6	40.8	9%	128.4	63.4	102%	103.19
Margin (%)	42%	43%		41%	31%		34%
PAT	32.0	30.6	5%	93.6	43.1	117%	72.06
Margin (%)	30%	32%		30%	21%		24%

*includes other income

- The revenue (including other income) stood at Rs. 313 Cr for 9M FY19 as against Rs. 204 Cr in 9M FY18 up by 53% YoY led by increase in volumes of Vitamin D3 segment and better realizations
- EBITDA margins stands at 41% for 9M FY19 as against 31 % in 9M FY18
- PAT for 9M FY19 stood at Rs. 94 Cr; growth of 117% YoY

Earnings Release

Un-audited Consolidated Results of DIL Limited:

DIL Limited (Consolidated Results)							
Particulars (Rs. Crs)	Q3 FY19	Q3 FY18	YoY%	9M FY19	9M FY18	YoY%	FY18
Revenue*	112.9	98.4	14.7%	324.2	210.5	54%	311.92
EBITDA*	46.0	39.6	16.2%	129.0	59.6	116%	101.96
Margin (%)	40.7%	40.2%		39.8%	28.3%		33%
PAT	28.1	26.5	6.0%	79.4	29.1	173%	54.84
Margin (%)	24.9%	26.9%		24.5%	13.8%		18%

*includes other income

Awards:

Fermenta Biotech Limited has received the below mentioned awards at India Pharma Awards 2018. These awards were given during the recently concluded Pharma week at CPhI India – South East Asia’s largest pharmaceutical event.

- 1. Excellence in Corporate Social Responsibility (Companies with turnover < Rs 500 crore)**
- 2. Excellence in Export Promotion**
- 3. Pharma International Excellence**

Fermenta Biotech also received the award in the category of Healthcare, Pharma and Biotech Manufacturing at the prestigious **Hindustan Times Thane Ratna Awards 2019**.

Business Updates:

Fermenta Biotech Limited has executed a 99 years lease for acquisition of land aggregating to about 40,000 sq. mts. from the Gujarat Industrial Development Corporation Authority, Ankleshwar, Saykha, for the future expansion and new projects.

The land acquisition is part of the company’s long-term capacity and product expansion plans. The expansion will be done in phases over the next few years and we expect to commence manufacturing under Phase 1 by end of FY 2020. The Phase 1 is expected to increase our total capacity by approximately 30%. The existing size of the Dahej facility is 30,689 sq. mts.

Earnings Release

Commenting on the performance, Mr. Satish Varma, Managing Director, Fermenta Biotech Limited said

“We are extremely pleased with our performance for the current year. In 9MFY19, we have surpassed the full year FY18 numbers in terms of Revenue and Profitability.

Vitamin D3 revenues has witnessed an overall growth of 54% in 9MFY19 on a YoY basis.

- Vitamin D3 (Humans) has witnessed a growth of 70% in 9MFY19 on a YoY basis.
- Vitamin D3 (Feed) has witnessed a growth of 46% in 9MFY19 on a YoY basis.

The sustained business momentum has led to our capex planning for the next level of growth. In this direction, we have recently signed a 99-year lease deed with GIDC, to acquire land measuring 40,000 sq. mts. to expand our capacities gradually over the next few years.

Our efforts in the enzymes manufacturing has been yielding results. The total revenue from the Enzymes business stood at Rs. 9 Crores for 9MFY19 as against FY 18 at Rs 5.7crores.

We believe the momentum in the business will continue in coming quarters and are confident of achieving ~25% revenue growth in FY19.”

Earnings Release

About DIL Limited:

DIL holds 91.2% equity stake in Fermenta Biotech Limited (FBL), which was incorporated in 1986.

FBL is engaged in manufacturing of Vitamin D3, other specialty APIs, biological enzymes and also offers integrated biotech based environmental solutions. FBL has 2 manufacturing facilities:

- Kullu in Himachal Pradesh – cGMP certified and currently manufactures Vitamin D3, specialty API's and Enzymes
- Dahej SEZ – set up in 2011 and manufactures Vitamin D3

DIL has developed premium office spaces named 'THANE ONE', with a total leasable area of 200,000 sq. ft., which is currently about 95% occupied.

For more information about the Company and its businesses, please visit our website www.dil.net

Safe Harbor:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

Company	Investor Relations Advisors
<p>DIL Limited CIN No: L99999MH1951PLC008485 Name: Sumesh Gandhi Email id: sumesh.gandhi@dil.net</p>	<p>Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Rahul Agarwal / Mandar Chavan Email id: rahul.agarwal@sgapl.net mandar.chavan@sgapl.net Tel No: +91 79770 90416 / +91 96993 82195</p>